A single intravenous dose of the potent osteoporosis drug zoledronic acid significantly improved bone mineral density (BMD) in frail elderly women living in long-term care facilities. Positive findings from the proof-of-concept randomized trial paves the way for an “essential” larger trial to study fracture reduction with bisphosphonate treatment in a frail elderly population. (Greenspan SL et al. JAMA Intern Med. doi:10.1001/jamainternmed.2015.0747 [published online April 13, 2015]).
Slomski A. Osteoporosis Drug May Benefit the Frail Elderly in Nursing Homes. JAMA. 2015;313(24):2416. doi:10.1001/jama.2015.6097
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: